Gino In
|
Title(s) | Assistant Professor of Clinical Medicine |
---|
Phone | +1 323 226 7622 |
---|
vCard | Download vCard |
---|
|
|
Biography University of Southern California, Los Angeles, CA | Fellowship | 2016 | Hematology/Oncology | SUNY Downstate Medical Center, Brooklyn, NY | Residency | 2011 | Internal Medicine | SUNY Downstate Medical Center, Brooklyn, NY | Internship | 2010 | | Ross University, North Brunswick Township, NJ | MD | 2010 | Medicine | Emory University, Atlanta, GA | MPH | 2006 | Environmental/Occupational Health | Emory University, Atlanta, GA | BS | 2002 | |
University of Southern California | | | Chief Medical Oncology Fellow |
Overview Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.
Medical Oncology, Skin Cancer, Melanoma, Acral Lentiginous Melanoma, Uveal Melanoma, Mucosal Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma, Merkel Cell Carcinoma, Dermatofibrosarcoma Protuberans, Porocarcinoma
Bibliographic
-
Miller KA, Wojcik KY, Cockburn MG, In GK, Hamilton AS, Milam JE. Prevalence and correlates of adherence to skin examination among adolescent and young adult survivors of melanoma from the Project Forward Study. Pediatr Blood Cancer. 2019 Nov 27; e28090. PMID: 31774240.
-
Vaidya P, Mehta A, Ragab O, Lin S, In GK. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019 Sep; 5(9):763-766. PMID: 31516991.
-
Adler BL, Smogorzewski J, Sierro T, Shauly O, Osipchuk D, Miller M, Mert M, Fong MW, Ganesh S, Han H, In GK, Maw TT, Smogorzewski M, Hu J, Ngo B, Lee D, Ahronowitz I. Skin cancer and dermatoses in a majority Hispanic population of solid organ transplant recipients. J Am Acad Dermatol. 2019 Aug 07. PMID: 31400454.
-
Snow A, Ricker C, In GK. Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation. BMJ Case Rep. 2019 Jun 20; 12(6). PMID: 31227566.
-
Li S, Song Y, Quach C, Guo H, Jang GB, Maazi H, Zhao S, Sands NA, Liu Q, In GK, Peng D, Yuan W, Machida K, Yu M, Akbari O, Hagiya A, Yang Y, Punj V, Tang L, Liang C. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019 04 12; 10(1):1693. PMID: 30979895.
-
Trodello C, Higgins S, Ahadiat O, Ragab O, In G, Hawkins M, Wysong A. Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. Dermatol Surg. 2019 02; 45(2):254-267. PMID: 30672860.
-
Lara KM, In GK, Matcuk GR, Mehta A, Hu JS. Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov; 4(10):1004-1006. PMID: 30450405.
-
Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature. Dermatol Surg. 2018 10; 44(10):1247-1261. PMID: 29894433.
-
In G, Mason J, Lin S, Newton PK, Kuhn P, Nieva J. Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Converg Sci Phys Oncol. 2017 Sep; 3(3). PMID: 30283700.
-
In GK, Mason J, Lin S, Newton P, Kuhn P, Nieva J.Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Convergent Science Physical Oncology. 2017; 3(3).
-
Miller KA, In GK, Jiang SY, Ahadiat O, Higgins S, Wysong A, Cockburn MG.Skin Cancer Prevention Among Hispanics: a Review of the Literature. Epidemiology. 2017.
-
In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. PMID: 28794805.
-
In GK, Nieva J.Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics for Non-Small Cell Lung Cancer. Transl Cancer Res. 2015; 4(4):340-355.
-
In G, Dorff T. Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies. Urol Clin North Am. 2015 Aug; 42(3):347-57. PMID: 26216822.
|
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
|